Biosimilar Infliximab Switching is Not Associated with Adverse Outcomes: A Real-World Effectiveness Analyses in a National US Cohort of US Military Veterans with Inflammatory Bowel Disease

被引：0

作者：

Hou, J. K. ^{[1
]}

Pham, C. ^{[2
]}

Sansgiry, S. ^{[3
]}

Modi, V. ^{[2
]}

Waljee, A. K. ^{[4
]}

机构：

[1] Baylor Coll Med, Sect Gastroenterol, 5207 Contour Pl, Houston, TX USA

[2] Baylor Coll Med, Med, Houston, TX USA

[3] Baylor Coll Med, Michael E DeBakey VA Med Ctr, Med, Houston, TX USA

[4] Ann Arbor VA Univ Michigan, Med, Ann Arbor, VA USA

来源：

JOURNAL OF CROHNS & COLITIS | 2023年 / 17卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

P750

引用

页码：880 / 881

页数：2

共 50 条

[1] BIOSIMILAR INFLIXIMAB SWITCHING IS NOT ASSOCIATED WITH ADVERSE OUTCOMES: A REAL-WORLD EFFECTIVENESS ANALYSES IN A NATIONAL COHORT OF US MILITARY VETERANS WITH INFLAMMATORY BOWEL DISEASE
Hou, Jason K.
Pham, Codey
Sansgiry, Shubhada
Modi, Varsha
Waljee, Akbar K.
GASTROENTEROLOGY, 2023, 164 (06) : S645 - S646
[2] MULTIPLE BIOSIMILAR INFLIXIMAB SWITCHING IS NOT ASSOCIATED WITH ADVERSE OUTCOMES IN INFLAMMATORY BOWEL DISEASE: A REAL-WORLD EFFECTIVENESS ANALYSES IN A NATIONAL US COHORT
Hou, Jason K.
Pham, Codey
Xu, Anthony
Sansgiry, Shubhada
Modi, Varsha
Waljee, Akbar
GASTROENTEROLOGY, 2024, 166 (05) : S503 - S503
[3] Multiple Biosimilar Infliximab Switching is Not Associated with Adverse Outcomes in Inflammatory Bowel Disease: A Real-World Effectiveness Analysis in a National US Cohort
Hou, J. K.
Pham, C.
Xu, A.
Sansgiry, S.
Modi, V.
Waljee, A.
JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1327 - I1327
[4] MULTIPLE BIOSIMILAR INFLIXIMAB SWITCHING IS NOT ASSOCIATED WITH DISEASE FLARE IN INFLAMMATORY BOWEL DISEASE: A REAL-WORLD EFFECTIVENESS ANALYSES IN A NATIONAL US COHORT
Hou, Jason
Pham, Codey
Xu, Anthony
Sansgiry, Shubhada
Modi, Varsha
Waljee, Akbar
INFLAMMATORY BOWEL DISEASES, 2024, 30 : S7 - S7
[5] MULTIPLE BIOSIMILAR INFLIXIMAB SWITCHING IS NOT ASSOCIATED WITH DISEASE FLARE IN INFLAMMATORY BOWEL DISEASE: A REAL-WORLD EFFECTIVENESS ANALYSES IN A NATIONAL US COHORT
Hou, Jason
Pham, Codey
Xu, Anthony
Sansgiry, Shubhada
Modi, Varsha
Waljee, Akbar
GASTROENTEROLOGY, 2024, 166 (03) : S9 - S9
[6] PATTERNS OF STEROID USE AMONG A REAL-WORLD NATIONAL COHORT VETERANS WITH INFLAMMATORY BOWEL DISEASE ON MAINTENANCE INFLIXIMAB
Pham, Codey
Xu, Anthony
Sansgiry, Shubhada
Waljee, Akbar K.
Hou, Jason K.
GASTROENTEROLOGY, 2023, 164 (06) : S1128 - S1128
[7] Multiple infliximab biosimilar switches appear to be safe and effective in a real-world inflammatory bowel disease cohort
Gros, Beatriz
Plevris, Nikolas
Constantine-Cooke, Nathan
Lyons, Mathew
O'Hare, Claire
Noble, Colin
Arnott, Ian D.
Jones, Gareth-Rhys
Lees, Charlie W.
Derikx, Lauranne A. A. P.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2023, : 179 - 188
[8] MULTIPLE INFLIXIMAB BIOSIMILAR SWITCHES APPEAR TO BE SAFE AND EFFECTIVE IN A REAL-WORLD INFLAMMATORY BOWEL DISEASE COHORT
Gros, Beatriz
Plevris, Nikolas
Constantine-Cooke, Nathan
Lyons, Mathew
O'Hare, Claire
Noble, Colin L.
Arnott, Ian
Jones, Gareth-Rhys
Lees, Charlie W.
Derikx, Lauranne
GASTROENTEROLOGY, 2023, 164 (06) : S94 - S95
[9] Multiple infliximab biosimilar switches appear to be safe and effective in a real-world inflammatory bowel disease cohort
Gros, B.
Plevris, N.
Constantine-Cooke, N.
Lyons, M.
O'Hare, C.
Noble, C.
Arnott, I. D.
Jones, G. R.
Lees, C. W.
Derikx, L. A. A. P.
JOURNAL OF CROHNS & COLITIS, 2023, 17 : 876 - 876
[10] Efficacy and safety of biosimilar versus originator infliximab in patients with inflammatory bowel disease: A real-world cohort analysis
Peeyush Kumar
Sudheer K. Vuyyuru
Bhaskar Kante
Saurabh Kedia
Pabitra Sahu
Mukesh Kumar Ranjan
Sandeep Mundhra
Rithvik Golla
Mukesh Kumar
Shubi Virmani
Anvita Gupta
Nidhi Yadav
Govind Makharia
Vineet Ahuja
Indian Journal of Gastroenterology, 2022, 41 : 446 - 455

← 1 2 3 4 5 →